Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Switching from abacavir/lamivudine plus nevirapine to abacavir/lamivudine/dolutegravir in virologically controlled HIV-infected adults (SWAD study).
Allavena C, Volteau C, André-Garnier E, Guimard T, Hall N, Khatchatourian L, Morrier M, Billaud E, Rodallec A, Reliquet V, Jovelin T, Le Guen L, Perré P, Grégoire M, Raffi F. Allavena C, et al. Among authors: khatchatourian l. Med Mal Infect. 2019 Oct;49(7):505-510. doi: 10.1016/j.medmal.2018.11.012. Epub 2018 Dec 21. Med Mal Infect. 2019. PMID: 30583867
Optimizing the virological success of tenofovir DF/FTC/rilpivirine in HIV-infected naive and virologically suppressed patients through strict clinical and virological selection.
Bernaud C, Khatchatourian L, Rodallec A, Hall N, Perre P, Morrier M, Pineau S, Jovelin T, André-Garnier E, Raffi F, Allavena C. Bernaud C, et al. Among authors: khatchatourian l. Infect Dis (Lond). 2016 Oct;48(10):754-9. doi: 10.1080/23744235.2016.1194528. Epub 2016 Jul 8. Infect Dis (Lond). 2016. PMID: 27389932
Impact of baseline plasma HIV-1 RNA and time to virological suppression on virological rebound according to first-line antiretroviral regimen.
Raffi F, Hanf M, Ferry T, Khatchatourian L, Joly V, Pugliese P, Katlama C, Robineau O, Chirouze C, Jacomet C, Delobel P, Poizot-Martin I, Ravaux I, Duvivier C, Gagneux-Brunon A, Rey D, Reynes J, May T, Bani-Sadr F, Hoen B, Morrier M, Cabie A, Allavena C; Dat’AIDS Study Group. Raffi F, et al. Among authors: khatchatourian l. J Antimicrob Chemother. 2017 Dec 1;72(12):3425-3434. doi: 10.1093/jac/dkx300. J Antimicrob Chemother. 2017. PMID: 28961719
Effect of Swine Glyco-humanized Polyclonal Neutralizing Antibody on Survival and Respiratory Failure in Patients Hospitalized With Severe COVID-19: A Randomized, Placebo-Controlled Trial.
Gaborit B, Vanhove B, Lacombe K, Guimard T, Hocqueloux L, Perrier L, Dubee V, Ferre V, Bressollette C, Josien R, Thuaut AL, Vibet MA, Jobert A, Dailly E, Ader F, Brouard S, Duvaux O, Raffi F; POLYCOR study group. Gaborit B, et al. Open Forum Infect Dis. 2023 Oct 20;10(11):ofad525. doi: 10.1093/ofid/ofad525. eCollection 2023 Nov. Open Forum Infect Dis. 2023. PMID: 37942459 Free PMC article.
Impact of baseline plasma HIV-1 RNA and time to virological suppression on virological rebound according to first-line antiretroviral regimen.
Raffi F, Hanf M, Ferry T, Khatchatourian L, Joly V, Pugliese P, Katlama C, Robineau O, Chirouze C, Jacomet C, Delobel P, Poizot-Martin I, Ravaux I, Duvivier C, Gagneux-Brunon A, Rey D, Reynes J, May T, Bani-Sadr F, Hoen B, Morrier M, Cabie A, Allavena C; Dat’AIDS Study Group. Raffi F, et al. Among authors: khatchatourian l. J Antimicrob Chemother. 2017 Dec 1;72(12):3502. doi: 10.1093/jac/dkx383. J Antimicrob Chemother. 2017. PMID: 29121210 No abstract available.
34 results